--- title: "OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 10,131 Shares of Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/297761160.md" description: "OrthoPediatrics Director David Pelizzon sold 10,131 shares on September 1 at $23.10, reducing his stake by 0.15%. This follows Squadron Capital's sale of 326,700 shares in late August. Despite insider selling, the company reported better-than-expected quarterly results with revenue of $70.51 million and a loss of $0.26 per share. Analysts maintain a 'Moderate Buy' rating with a $26.44 price target, while institutional investors like Goldman Sachs and Millennium Management increased their positions." datetime: "2026-09-02T09:23:12.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297761160.md) - [en](https://longbridge.com/en/news/297761160.md) - [zh-HK](https://longbridge.com/zh-HK/news/297761160.md) generator: "portal-rs" --- # OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 10,131 Shares of Stock ## Key Points - **Squadron Capital sold 326,700 OrthoPediatrics shares** at an average $23.04, generating approximately $7.53 million and reducing its position by 4.76% to 6.54 million shares. - OrthoPediatrics reported better-than-expected quarterly results, with a loss of $0.26 per share versus the $0.30 consensus estimate and revenue of $70.51 million versus $68.21 million expected. - Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $26.44; institutional investors own approximately 69.05% of the company. OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) Director David Pelizzon sold 10,131 shares of the business's stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.10, for a total transaction of $234,026.10. Following the sale, the director owned 6,526,633 shares of the company's stock, valued at approximately $150,765,222.30. This represents a 0.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. ## OrthoPediatrics Price Performance NASDAQ KIDS opened at $23.00 on Wednesday. The stock has a market capitalization of $600.53 million, a price-to-earnings ratio of -13.69 and a beta of 0.98. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The business's fifty day moving average price is $21.61 and its 200-day moving average price is $18.76. OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. On average, equities analysts predict that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year. ## OrthoPediatrics News Roundup * * * * * * Here are the key news stories impacting OrthoPediatrics this week: - Positive Sentiment: Analysts assigned OrthoPediatrics a consensus price target of **$26.44**, implying potential upside from recent trading levels and signaling continued confidence in the company’s long-term growth prospects. OrthoPediatrics Receives $26.44 Consensus Price Target - Neutral Sentiment: The reported sales appear across related director, major-shareholder and beneficial-ownership filings, meaning some transactions may represent overlapping disclosures rather than entirely separate blocks of stock. After the transactions, the reporting holders still controlled approximately **6.53 million shares**, indicating continued substantial exposure to KIDS. SEC Insider Transaction Filing - Negative Sentiment: Director David R. Pelizzon and major shareholder Jennifer N. Pritzker reported sales of **326,700 shares** on August 28 at an average price of $23.04, worth approximately **$7.53 million**. Each reduced their reported ownership by 4.76%, which may pressure the stock or raise concerns about insider confidence, although both retained large positions. SEC Major Shareholder Ownership Filing - Negative Sentiment: The same holders, along with Squadron Capital LLC, reported additional sales of **10,131 shares** on September 1 at $23.10, worth approximately $234,000 per reported transaction. The small 0.15% ownership reduction is less significant by itself, but reinforces the near-term insider-selling overhang. SEC Ownership Filing ## Institutional Trading of OrthoPediatrics Several institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock worth $246,000 after purchasing an additional 645 shares in the last quarter. Millennium Management LLC lifted its holdings in OrthoPediatrics by 55.3% in the 1st quarter. Millennium Management LLC now owns 656,578 shares of the company's stock worth $16,172,000 after purchasing an additional 233,873 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in OrthoPediatrics by 112.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company's stock worth $4,937,000 after purchasing an additional 106,041 shares during the period. Jane Street Group LLC bought a new position in OrthoPediatrics in the 1st quarter worth approximately $389,000. Finally, American Century Companies Inc. grew its holdings in OrthoPediatrics by 12.5% during the 2nd quarter. American Century Companies Inc. now owns 34,486 shares of the company's stock valued at $741,000 after buying an additional 3,828 shares in the last quarter. Hedge funds and other institutional investors own 69.05% of the company's stock. ## Wall Street Analyst Weigh In KIDS has been the topic of several recent research reports. Weiss Ratings upgraded shares of OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, August 5th. Piper Sandler reaffirmed an "overweight" rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Needham & Company LLC boosted their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 price target on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, TD Cowen reissued a "buy" rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $26.44. **Check Out Our Latest Stock Analysis on KIDS** ## OrthoPediatrics Company Profile (Get Free Report) OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries. The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis. ## Featured Articles - Five stocks we like better than OrthoPediatrics - Dutch Bros Sell-Off Creates a Growth Opportunity - NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat - Is Abercrombie & Fitch's Hot Streak Just Getting Started? - Medtronic’s Stars Are Aligning for a Price Recovery *This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\].* Insider Buying or Selling at OrthoPediatrics? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for OrthoPediatrics and related companies. From Our Partners A Simple Guide to Options Trading While It's Still Free A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal... True Market Insiders Buy this stock tomorrow morning A new strategy called Sell This, Buy That aims to help investors rotate out of overpriced AI stocks before a p... Chaikin Analytics My top 3 AI picks for the next decade Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A... The Oxford Club A “bloodbath” Is Coming Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co... TradeSmith Rickards Predicts: Trump to buy tiny $2 stock? Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la... Paradigm Press These 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI Elon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture afte... Stansberry Research The trade I’ve been waiting for since 2011 Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc... Traders Agency Your book is inside The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ... Profits Run ### Related Stocks - [KIDS.US](https://longbridge.com/en/quote/KIDS.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) ## Related News & Research - [OrthoPediatrics director, 10% owner David R. Pelizzon disposes of USD 6.35 million in common shares](https://longbridge.com/en/news/298640456.md) - [OrthoPediatrics (NASDAQ:KIDS) Sees Strong Trading Volume - What's Next?](https://longbridge.com/en/news/298624585.md) - [OrthoPediatrics Director David R. Pelizzon reports disposal of common shares worth $939,792.5](https://longbridge.com/en/news/297094101.md) - [Goldman Sachs (GS) Completes $11.7 Billion In New Private Equity Fundraising](https://longbridge.com/en/news/299273779.md) - [Duke Robotics names Avi Levin CFO, replacing Shlomo Zakai](https://longbridge.com/en/news/299320669.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**